Lexeo Therapeutics Receives Price Target Increases Following Positive LX2020 Clinical Data
Lexeo Therapeutics (LXEO) has seen significant upward revisions to its stock price targets from major analysts, including Raymond James and Cantor Fitzgerald. This momentum follows the release of interim data from a Phase I/II clinical trial evaluating LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy. The positive clinical results have bolstered investor confidence in Lexeo's pipeline. Notably, Raymond James has upgraded its outlook on the company to a 'Strong Buy,' reflecting optimism regarding the therapeutic potential and market positioning of the LX2020 asset.

Topics: analyst upgrade biotechnology clinical trial results